These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6393864)

  • 41. Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
    DiTusa C; Kozar MP; Pybus B; Sousa J; Berman J; Gettayacamin M; Im-erbsin R; Tungtaeng A; Ohrt C
    J Parasitol; 2014 Oct; 100(5):671-3. PubMed ID: 24780070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of folic and folinic acids in the activities of cycloguanil and WR99210 against Plasmodium falciparum in erythrocytic culture.
    Yeo AE; Seymour KK; Rieckmann KH; Christopherson RI
    Ann Trop Med Parasitol; 1997 Jan; 91(1):17-23. PubMed ID: 9093425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.
    Leslie T; Mayan MI; Hasan MA; Safi MH; Klinkenberg E; Whitty CJ; Rowland M
    JAMA; 2007 May; 297(20):2201-9. PubMed ID: 17519409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.
    Fidock DA; Wellems TE
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10931-6. PubMed ID: 9380737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana.
    Muehlen M; Schreiber J; Ehrhardt S; Otchwemah R; Jelinek T; Bienzle U; Mockenhaupt FP
    Trop Med Int Health; 2004 Mar; 9(3):361-3. PubMed ID: 14996365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The activity of triple combinations of antifolate biguanides, with and without folinic acid, against plasmodium falciparum in vitro.
    Yeo AE; Rieckmann KH
    Ann Trop Med Parasitol; 1997 Apr; 91(3):247-51. PubMed ID: 9229018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro susceptibility studies of Plasmodium falciparum isolates and clones against type II antifolate drugs.
    Ang HH; Lam CK; Wah MJ
    Chemotherapy; 1996; 42(5):318-23. PubMed ID: 8874969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance.
    Foote SJ; Galatis D; Cowman AF
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):3014-7. PubMed ID: 2183221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of the pyrimethamine and cycloguanil sensitivities of the pre-erythrocytic and erythrocytic stages of drug-sensitive and -resistant strains of Plasmodium yoelii.
    Howells RE; Gilles HM; Bent NS
    Ann Trop Med Parasitol; 1985 Jun; 79(3):247-51. PubMed ID: 4026437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. UK malaria treatment guidelines.
    Lalloo DG; Shingadia D; Pasvol G; Chiodini PL; Whitty CJ; Beeching NJ; Hill DR; Warrell DA; Bannister BA;
    J Infect; 2007 Feb; 54(2):111-21. PubMed ID: 17215045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacology of the antimalarials. A rational approach to the therapy of resistant falciparum malaria.
    Hunsicker LG
    Arch Intern Med; 1969 Jun; 123(6):645-9. PubMed ID: 4890439
    [No Abstract]   [Full Text] [Related]  

  • 52. Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine).
    Schmidt LH; Crosby R; Rasco J; Vaughan D
    Antimicrob Agents Chemother; 1978 Jun; 13(6):1011-30. PubMed ID: 98104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
    Aubouy A; Jafari S; Huart V; Migot-Nabias F; Mayombo J; Durand R; Bakary M; Le Bras J; Deloron P
    J Antimicrob Chemother; 2003 Jul; 52(1):43-9. PubMed ID: 12805261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies on the toxicity and action of diaminodiphenyl-sulfone (DDS) in avian and simian malaria.
    RAMAKRISHNAN SP; BASU PC; SINGH H; SINGH N
    Bull World Health Organ; 1962; 27(2):213-21. PubMed ID: 13990624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
    Fryauff DJ; Sumawinata I; Purnomo ; Richie TL; Tjitra E; Bangs MJ; Kadir A; Ingkokusumo G
    Am J Trop Med Hyg; 1999 Apr; 60(4):542-6. PubMed ID: 10348226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Susceptibility studies of Plasmodium falciparum isolates and clones against cycloguanil and pyrimethamine using the modified in vitro microtechnique.
    Ang HH; Chan KL; Mak JW
    J Parasitol; 1996 Dec; 82(6):1029-31. PubMed ID: 8973418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
    Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
    Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum.
    Wooden JM; Hartwell LH; Vasquez B; Sibley CH
    Mol Biochem Parasitol; 1997 Mar; 85(1):25-40. PubMed ID: 9108546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists.
    Canfield CJ; Milhous WK; Ager AL; Rossan RN; Sweeney TR; Lewis NJ; Jacobus DP
    Am J Trop Med Hyg; 1993 Jul; 49(1):121-6. PubMed ID: 8352384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum.
    Alam MT; Bora H; Bharti PK; Saifi MA; Das MK; Dev V; Kumar A; Singh N; Dash AP; Das B; Wajihullah ; Sharma YD
    Antimicrob Agents Chemother; 2007 Mar; 51(3):857-63. PubMed ID: 17194833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.